Admedus (ASX: AHZ) today announced the transaction to acquire an established manufacturing site from Genzyme Australia to facilitate scaled-up production of its lead regenerative tissue product CardioCel® has now been completed. The transaction was completed on the 31st of December, 2013 in accordance to the share purchase agreement.
